Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Catalent
Biotech
FDA skips AdComm for Sarepta's DMD therapy, sets decision date
The FDA won’t be holding an advisory panel meeting for Sarepta’s SRP-9001, which could become the first gene therapy for Duchenne muscular dystrophy.
Gabrielle Masson
Feb 28, 2023 8:00pm
Exelixis goes 3 in 3 with $30M for 3 Catalent programs
Nov 3, 2022 1:20pm
Catalent shakes up leadership, taps new CEO—Chutes & Ladders
Jul 8, 2022 9:30am